作为胰岛素辅助剂的无毒双核 (IV) 复合物改善了链毒素诱导的糖尿病大鼠的血糖控制
Mateus S Lopes1, Gabriel B Baptistella2, Giovana G Nunes2
1Post-Graduation Program in Pharmaceutical Sciences, Federal University of Paraná, Curitiba 80210-170, PR, Brazil.
Pharmaceuticals (Basel, Switzerland)
|April 27, 2024
概括
氧化瓦纳 (IV) 复合体 (Vox2) 显示为糖尿病的辅助疗法具有前途. 当与胰岛素结合时,Vox2可显著降低糖尿病大鼠的血糖水平,而不会引起毒性.
科学领域:
- 无机化学 无机化学 有机化学
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病 (DM) 的并发症对医疗保健造成了重大负担.
- 包括化合物在内的辅助疗法正在探索,以改善血糖控制.
- 胰岛素治疗可能会产生相关的副作用,需要替代性或补充性治疗.
研究的目的:
- 为了研究氧化 (IV) 复合物的抗糖尿病和抗氧化作用,Vox2.2.
- 评估Vox2作为糖尿病的潜在辅助疗法.
- 在临床前模型中评估Vox2的安全性.
主要方法:
- 诱导链毒素 (STZ) 的糖尿病大鼠被口服Vox2 (30和100毫克/公斤) 持续12天.
- 该研究评估了血糖水平,胰腺谷氨 (GSH) 水平以及肝脏和脏毒性的标志物.
- Vox2单独和与胰岛素结合进行了测试.
主要成果:
- 100mg/kg的Vox2与胰岛素相结合,在STZ大鼠中降低了血糖的3.4倍,达到正常血糖水平.
- 与单独胰岛素相比,组合疗法显示了39% (30 mg/kg) 和65% (100 mg/kg) 的额外血糖降低.
- Vox2治疗增加了胰腺GSH水平的2.5倍,并且没有显著的胃肠道,肝脏或脏毒性.
结论:
- 氧化瓦纳 (IV) 复合体 (Vox2) 当作为胰岛素治疗的辅助剂使用时,表现出显著的抗糖尿病作用.
- 通过增加胰腺GSH水平,Vox2显示出抗氧化特性.
- Vox2为糖尿病管理提供了潜在的安全有效的补充治疗方法.
相关概念视频
Insulin Secretory Vesicles
4.9K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.9K
Insulin: Dosing Regimen and Adverse Effects
168
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
168
Insulin: Biosynthesis, Chemistry, and Preparation
374
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
374
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Hormones Regulating Blood Glucose
3.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.3K


